CLDI Calidi Biotherapeutics
Calidi Biotherapeutics earnings company data as of 4:47 AM ET 10/22
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 12 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | — | -2.94 | — |
| Rev | — | $18.7M | — |
Insider trades
Open-market buys and sales by CLDI's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $1,237 sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Allan Camaisa DirectorSale$1,237 850 shares at $1.46 1.1% of stakeTraded Dec 12, 2025 Filed Dec 16, 2025
SEC filings
Recent issuer filings from EDGAR, 25 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 3.01,8.01,9.01 | Filing Doc | |
| 8-K | 1.01,8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 3.03,5.03,9.01 | Filing Doc | |
| 8-K | 1.01,1.02,2.03,9.01 | Filing Doc | |
| 8-K | 5.02,7.01,8.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| DEFA14A | Filing Doc | ||
| 8-K | 1.01,3.02,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 1.01,3.02,9.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| 8-K | 5.02,8.01,9.01 | Filing Doc | |
| SCHEDULE 13D | — | Filing Doc | |
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 1.01,3.02,8.01,9.01 | Filing Doc | |
| SCHEDULE 13D | — | Filing Doc | |
| 424B5 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.